Precision BioSciences Inc. (DTIL) - Forward P/S Multiple
Patent protection for ARCUS software creates a long-term foundation for license monetization for Precision BioSciences (DTIL). The expected P/S ratio clearly demonstrates the business valuation dynamics, where 4.90 represents the current metric level. Precision BioSciences is actively developing hepatitis B therapies, while high barriers to entry in bioengineering and a shortage of skilled personnel effectively limit competition within the segment.
Analytical breakdowns for Precision BioSciences
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- business debt structure and liquidity details:
Debt to Equity Precision BioSciences|DTIL - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Precision BioSciences, Inc.|DTIL - Company Total Debt|Debts to Book Capitalization Precision BioSciences, Inc.|DTIL - Long-Term Debt Volume|Company Short-Term Debts Precision BioSciences|Quick Liquidity precisionbiosciences.com
- financial results and valuation multiples details:
DTIL - Company Profit|Projected Future Earnings Precision BioSciences|DTIL - Price to Earnings Ratio|Forward P/E Multiple Precision BioSciences|DTIL - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences, Inc.|DTIL - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Precision BioSciences|DTIL - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months precisionbiosciences.com|DTIL - Net earnings per one share growth for the current year|Earnings growth forecast for next year Precision BioSciences
- sales volume and revenue indicators:
Analysis of all company metrics:Precision BioSciences DTIL
The forward P/S reflects the ratio of market capitalization to expected sales volume, allowing for an assessment of whether an asset is overvalued or undervalued relative to future cash flows. Amid geopolitical risks for Precision BioSciences (DTIL) affecting global research and patents, the projected P/S metric helps distinguish a fundamental discount from a systemic devaluation of the business caused by operational barriers.
Analysis of competing companies
Tempus AI, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales QGEN|Ionis Pharma - Forward P/S Multiple|RGEN: Price-to-Projected Revenue Ratio|RNA: Forward P/S Multiple|CRSP - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio GeneDx|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|Market Cap to Expected Sales Ratio Sarepta Corp|Forward P/S Multiple TWST (Twist Bioscience)|TXG - Forward Price-to-Revenue Multiple|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke Therapeutics Inc STOK|BLFS: Forward P/S Multiple|Market Cap to Future Revenue Ratio Wave Pharma (WVE)|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|Market Cap to Projected Revenue SION (sionnatx.com)|Forward P/S Multiple PRME|Forward Price-to-Revenue Multiple Taysha Gene Therapies Inc TSHA|Forward P/S Multiple QURE (uniQure Corp)|MeiraGTx Corp (MGTX) - Market Cap to Future Revenue Ratio|RGNX - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio solidbio.com SLDB|OCGN: Forward P/S Multiple|Market Cap to Projected Revenue PACB|Forward Price-to-Revenue Multiple BNTC|DSGN (Design Corp) - Price to Expected Revenue Ratio|Forward P/S Multiple RCKT|Market Cap to Expected Sales Ratio 4dmoleculartherapeutics.com|Price-to-Projected Revenue Ratio Lexeo Therapeutics, Inc. LXEO|Korro Bio Inc. - Price-to-Projected Revenue Ratio|Editas - Forward P/S Multiple|SLN (Silence Therapeutics Corp) - Market Cap to Projected Revenue|proqr.com (PRQR) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue CDXS|SGMO (Sangamo Therapeutics, Inc.) - Forward P/S Multiple|Forward P/S Multiple Nautilus Biotechnology Inc|Price-to-Projected Revenue Ratio Metagenomi, Inc (MGX)|GBIO: Future Price to Revenue|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|Forward Price to Sales XCUR|Celsion Corporation - Forward P/S Multiple|Market Cap to Future Revenue Ratio Phio Pharmaceuticals|MBIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple TransCode Therapeutics, Inc.|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|adnas.com (APDN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio bluebird bio (BLUE)|Market Cap to Expected Sales Ratio immunoprecise.com|Forward P/S Multiple OMGA (Omega)|Market Cap to Expected Sales Ratio Singular Genomics Corp (OMIC)|RGLS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio syros.com|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TCON|Forward Price-to-Revenue Multiple UBX
